Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
47.85
+1.30 (2.79%)
At close: Aug 13, 2025, 4:00 PM
47.67
-0.18 (-0.38%)
Pre-market: Aug 14, 2025, 9:26 AM EDT
BMY Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
34,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,398,944
Profits / Employee
$148,065
Market Cap
97.40B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34,100 | 0 | - |
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
Dec 31, 2018 | 23,300 | -400 | -1.69% |
Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
Dec 31, 2016 | 25,000 | 0 | - |
Dec 31, 2015 | 25,000 | 0 | - |
Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
Dec 31, 2013 | 28,000 | 0 | - |
Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
Dec 31, 2011 | 27,000 | 0 | - |
Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
Dec 31, 2006 | 43,000 | 0 | - |
Dec 31, 2005 | 43,000 | 0 | - |
Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
Dec 31, 2003 | 44,000 | 0 | - |
Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
Dec 31, 1999 | 54,500 | -200 | -0.37% |
Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
Dec 31, 1993 | 49,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BMY News
- 6 days ago - 3 SWANs On Sale - Seeking Alpha
- 9 days ago - Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity - Seeking Alpha
- 9 days ago - Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Business Wire
- 10 days ago - Bristol-Myers Squibb: Buy The Weakness - Seeking Alpha
- 11 days ago - Bristol-Myers Squibb: Declines Have Gone Too Far - Seeking Alpha
- 12 days ago - Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields - Seeking Alpha
- 12 days ago - Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline - Seeking Alpha
- 12 days ago - Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade) - Seeking Alpha